BioMedLib Search Engine [ goto HOMEPAGE ]

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Characteristics of patients with stage III colon adenocarcinoma who fail to receive guideline-recommended treatment.

BACKGROUND: Many patients with stage III colon adenocarcinoma do not receive adjuvant chemotherapy despite the proven survival advantage it offers.

To enhance the provision of optimal cancer care, patient characteristics associated with not receiving guideline-adherent treatment must be identified among patients with operable, stage III colon adenocarcinoma.

METHODS: This was a population-based, retrospective study of all patients who underwent surgery for stage III colon adenocarcinoma diagnosed from 2002 through 2005 in Alberta, Canada.

RESULTS: Of the 772 patients who underwent surgery for stage III colon adenocarcinoma and met the eligibility criteria, 618 patients (80%) had a consultation with an oncologist.

CONCLUSIONS: The current results indicated that the proportion of patients with stage III colon adenocarcinoma who did not receive treatment according to evidence-based guidelines was appreciable.

[MeSH-major] Adenocarcinoma / drug therapy. Chemotherapy, Adjuvant. Colonic Neoplasms / drug therapy. Guideline Adherence

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] © 2010 American Cancer Society.

(PMID = 20578180.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Grant] Canada / Canadian Institutes of Health Research / /

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Expression and prognostic significance of APAF-1, caspase-8 and caspase-9 in stage II/III colon carcinoma: caspase-8 and caspase-9 is associated with poor prognosis.

To study their prognostic influence in colon carcinoma, expression of APAF-1, caspase-8 and caspase-9 was determined by immunohistochemistry in normal colon mucosa (n = 8) and R0-resected stage II/III colon carcinomas (n >or= 124) using a semiquantitative score.

In normal colon, APAF-1 and caspase-8 are most strongly expressed in the luminal surface epithelium, whereas caspase-9 is expressed all along the crypt axis.

In colon carcinomas, there is considerable variability in the expression of these proapoptotic factors, although complete loss of caspase-8 and caspase-9 is rare.

The influence of caspase-8 expression was mainly seen in patients with stage III colon carcinoma (p = 0.011), whereas the prognostic influence of caspase-9 expression was significant in stage II cases (p = 0.037) and just failed to be significant in stage III tumors (p = 0.0581).

Our data suggest that, in colon carcinomas, expression of caspase-8 and caspase-9 is significantly associated with poor survival.

Caspase-9 may be an independent prognosticator in colon carcinoma.

[MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Apoptotic Protease-Activating Factor 1 / metabolism. Biomarkers, Tumor / metabolism. Caspase 8 / metabolism. Caspase 9 / metabolism. Colonic Neoplasms / metabolism

[MeSH-minor] Aged. Colon / metabolism. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20013803.001).

[ISSN] 1097-0215

[Journal-full-title] International journal of cancer

[ISO-abbreviation] Int. J. Cancer

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / APAF1 protein, human; 0 / Apoptotic Protease-Activating Factor 1; 0 / Biomarkers, Tumor; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma.

In this study, we investigated the expression of fascin in 228 advanced colonic adenocarcinoma patients with a long follow-up.

Fascin correlated significantly with sex, tumour grade and stage, mucinous differentiation, number of metastatic lymph nodes, extranodal tumour extension, and the occurrence of distant metastases.

[MeSH-major] Adenocarcinoma / metabolism. Carrier Proteins / metabolism. Colonic Neoplasms / metabolism. Microfilament Proteins / metabolism

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer. 1993 Feb 15;71(4):1368-83 [8435813.001]

[Cites] J Cutan Pathol. 2002 Aug;29(7):430-8 [12139639.001]

[Cites] Am J Pathol. 1996 Feb;148(2):593-600 [8579121.001]

[Cites] In Vivo. 1996 Mar-Apr;10(2):153-60 [8744794.001]

[Cites] J Cell Biol. 1996 Sep;134(5):1271-81 [8794867.001]

[Cites] Hum Pathol. 1996 Nov;27(11):1124-34 [8912819.001]

[Cites] Dis Colon Rectum. 1997 Jan;40(1):15-24 [9102255.001]

[Cites] Mol Biol Cell. 1997 Nov;8(11):2345-63 [9362073.001]

[Cites] Mol Biol Cell. 1998 May;9(5):993-1006 [9571235.001]

[Cites] J Cell Biol. 1998 Oct 5;143(1):121-33 [9763425.001]

[Cites] J Biol Chem. 1999 Feb 26;274(9):5443-53 [10026156.001]

[Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308 [15537574.001]

[Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]

[Cites] Am J Pathol. 2003 Jan;162(1):69-80 [12507891.001]

[Cites] J Clin Oncol. 2003 Jan 15;21(2):241-50 [12525515.001]

[Cites] Br J Cancer. 2003 Feb 24;88(4):537-47 [12592367.001]

[Cites] Eur J Cancer. 2003 Apr;39(6):718-27 [12651195.001]

[Cites] Lung Cancer. 2003 Nov;42(2):203-13 [14568688.001]

[Cites] J Clin Oncol. 2004 May 1;22(9):1572-82 [15117979.001]

[Cites] Histopathology. 1986 May;10(5):437-59 [3721406.001]

[Cites] J Cell Biol. 1986 Aug;103(2):631-40 [3525578.001]

[Cites] Cell Struct Funct. 1988 Oct;13(5):373-85 [3224379.001]

[Cites] Oncology. 2004;67(3-4):262-70 [15557788.001]

[Cites] Surg Oncol. 2004 Aug-Nov;13(2-3):93-101 [15572091.001]

[Cites] Clin Cancer Res. 2005 Jan 1;11(1):186-92 [15671545.001]

[Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]

[Cites] Clin Cancer Res. 2005 Apr 1;11(7):2597-605 [15814639.001]

[Cites] Int J Biochem Cell Biol. 2005 Sep;37(9):1787-804 [16002322.001]

[Cites] Hum Pathol. 2005 Jul;36(7):741-6 [16084942.001]

[Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):355-62 [16185662.001]

[Cites] Semin Oncol. 2005 Dec;32(6 Suppl 8):11-4 [16360006.001]

[Cites] Clin Colorectal Cancer. 2006 May;6(1):38-45 [16796790.001]

[Cites] Eur J Cardiothorac Surg. 2006 Sep;30(3):538-42 [16870459.001]

[Cites] J Clin Pathol. 2006 Sep;59(9):958-64 [16524962.001]

[Cites] BMC Cancer. 2006;6:241 [17029629.001]

[Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1362-6 [14571738.001]

[Cites] J Histochem Cytochem. 2000 Feb;48(2):163-6 [10639482.001]

[Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]

[Cites] Br J Cancer. 2000 Oct;83(7):870-3 [10970687.001]

[Cites] Clin Exp Metastasis. 2000;18(1):83-8 [11206843.001]

[Cites] J Cell Biol. 2001 Mar 19;152(6):1169-82 [11257118.001]

[Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]

[Cites] Cancer. 2001 Dec 1;92(11):2754-9 [11753948.001]

[Cites] Bioessays. 2002 Apr;24(4):350-61 [11948621.001]

[Cites] Am J Clin Pathol. 2002 Jul;118(1):52-9 [12109856.001]

[Cites] DNA Cell Biol. 1994 Aug;13(8):821-7 [8068206.001]

(PMID = 17375048.001).

[ISSN] 0007-0920

[Journal-full-title] British journal of cancer

[ISO-abbreviation] Br. J. Cancer

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin

[Other-IDs] NLM/ PMC2360113

   

Advertisement

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (1989-2002).

METHODS: Two hundred and eighty-six patients with Union International Contre Cancer (UICC) stage II and III rectal adenocarcinomas, who underwent resection by conventional surgical techniques (low anterior or abdominoperineal resection), received either postoperative (n=233) or preoperative (n=53) radiochemotherapy from January 1989 until July 2002.

RESULTS: Anemia before radiochemotherapy was an independent prognostic factor for improved DFS (risk ratio 0.76, P=0.04) as well as stage, grading, R status (free radial margins), type of surgery, carcinoembryonic antigen (CEA) levels, and gender.

Stage, grading, R status (free radial margins), type of surgery, CEA levels, and gender have predictive value for the outcome of rectal cancer.

[MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Anemia / etiology. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy

Genetic Alliance. consumer health - Anemia.

MedlinePlus Health Information. consumer health - Anemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] N Engl J Med. 1991 Mar 14;324(11):709-15 [1997835.001]

[Cites] Strahlenther Onkol. 2004 Jan;180(1):45-51 [14704844.001]

[Cites] Dis Colon Rectum. 1992 Nov;35(11):1057-65 [1425050.001]

[Cites] World J Surg. 1992 Sep-Oct;16(5):858-65 [1462620.001]

[Cites] Lancet. 1993 Feb 20;341(8843):457-60 [8094488.001]

[Cites] Dis Colon Rectum. 1993 Jun;36(6):564-72 [8500374.001]

[Cites] Dis Colon Rectum. 1994 Jan;37(1):73-87 [8287751.001]

[Cites] Am J Clin Oncol. 1995 Aug;18(4):277-81 [7625365.001]

[Cites] Int J Colorectal Dis. 1995;10(3):126-32 [7561427.001]

[Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):305-11 [9069301.001]

[Cites] Br J Surg. 1997 Mar;84(3):352-7 [9117306.001]

[Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1379-82 [9137502.001]

[Cites] Dis Colon Rectum. 1997 Jul;40(7):866-7 [9221868.001]

[Cites] Anticancer Res. 1997 Jul-Aug;17(4B):2935-8 [9329568.001]

[Cites] Strahlenther Onkol. 1998 Dec;174 Suppl 4:31-4 [9879345.001]

[Cites] Langenbecks Arch Surg. 1998 Dec;383(6):416-26 [9921941.001]

[Cites] Ann Surg. 1999 Oct;230(4):544-52; discussion 552-4 [10522724.001]

[Cites] J Clin Oncol. 1999 Aug;17(8):2412-8 [10561304.001]

[Cites] Cancer. 1999 Nov 15;86(10):1952-8 [10570418.001]

[Cites] Int J Biol Markers. 2000 Jan-Mar;15(1):51-5 [10763141.001]

[Cites] Int J Colorectal Dis. 2000 Feb;15(1):9-20 [10766086.001]

[Cites] Curr Opin Oncol. 2001 Jul;13(4):300-6 [11429489.001]

[Cites] J Clin Oncol. 2001 Sep 15;19(18):3895-902 [11559727.001]

[Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]

[Cites] Br J Surg. 1984 Jan;71(1):12-6 [6689962.001]

[Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]

[Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]

[Cites] Rev Invest Clin. 2001 Sep-Oct;53(5):388-95 [11795103.001]

[Cites] J Clin Oncol. 2002 Apr 1;20(7):1744-50 [11919230.001]

[Cites] J Clin Oncol. 2002 Apr 1;20(7):1751-8 [11919231.001]

[Cites] Eur J Cancer. 2002 May;38(7):919-36 [11978517.001]

[Cites] Am Surg. 2002 May;68(5):482-7 [12013294.001]

[Cites] Am J Surg. 2002 May;183(5):504-8 [12034381.001]

[Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):386-96 [12243812.001]

[Cites] Eur J Cancer Care (Engl). 2002 Sep;11(3):166-72 [12296832.001]

[Cites] J Exp Clin Cancer Res. 2002 Sep;21(3):329-35 [12385573.001]

[Cites] Surg Clin North Am. 2002 Oct;82(5):1035-58 [12507208.001]

[Cites] J Clin Oncol. 1992 Apr;10(4):549-57 [1548520.001]

(PMID = 16609990.001).

[ISSN] 1007-9327

[Journal-full-title] World journal of gastroenterology

[ISO-abbreviation] World J. Gastroenterol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] China

[Chemical-registry-number] U3P01618RT / Fluorouracil

[Other-IDs] NLM/ PMC4087509

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer.

PURPOSE: The Xeloda in Adjuvant Cancer Therapy trial, conducted in a white population of patients, established capecitabine (Xeloda) as adjuvant chemotherapy for Stage III colon cancer.

Given the ethnical difference in toxicity of adjuvant chemotherapy in colon cancer, this study was designed to evaluate the safety and efficacy of adjuvant capecitabine in Chinese patients with colon cancer.

METHODS: Chinese patients with curatively resected Stage III colon adenocarcinoma, who received adjuvant capecitabine, were entered into a prospective database.

CONCLUSIONS: A different toxicity profile of adjuvant capecitabine was noted in this study on Chinese patients with colon cancer compared with that reported in the Xeloda in Adjuvant Cancer Therapy trial, whereas the efficacy outcomes were comparable.

[MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Colonic Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives

Genetic Alliance. consumer health - Oral cancer.

Hazardous Substances Data Bank. CAPECITABINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17963003.001).

[ISSN] 0012-3706

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Clinical Trial; Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Prodrugs; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Concordance with clinical practice guidelines for adjuvant chemotherapy in patients with stage I-III colon cancer: experience in 2 Canadian provinces.

The American Society of Clinical Oncology and Cancer Care Ontario have recommended adjuvant chemotherapy for patients with high-risk stage II colon cancer.

We evaluated differences in concordance with guidelines in the treatment of patients with stage I-III colon cancer in the Canadian provinces of Newfoundland and Labrador and Ontario.

METHODS: We assessed clinical data and treatment from January 1999 to December 2000 for 130 patients from Newfoundland and Labrador and 315 patients from Ontario who had stage I-III colon cancer.

We evaluated factors affecting the use of chemotherapy in patients with stage II disease.

RESULTS: No patients received adjuvant therapy for stage I disease.

Forty-five of 52 patients (87%) in Newfoundland and Labrador and 108 of 115 patients (94%) in Ontario received adjuvant chemotherapy for stage III colon cancer.

Twenty of 55 patients (36%) in Newfoundland and Labrador and 44 of 116 patients (38%) in Ontario received adjuvant therapy for stage II disease.

There was a strong trend toward using chemotherapy in patients with stage II disease who were 50 years or younger, independent of high-risk status.

CONCLUSION: Concordance with CPGs for adjuvant chemotherapy in patients with stage II colon cancer was not optimal.

[MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Age Factors. Aged. Humans. Middle Aged. Multivariate Analysis. Newfoundland and Labrador. Ontario. Patient Selection. Registries. Risk Assessment

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] JAMA. 1999 Oct 20;282(15):1458-65 [10535437.001]

[Cites] Am J Gastroenterol. 2006 Jun;101(6):1320-8 [16771956.001]

[Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]

[Cites] Chronic Dis Can. 2000;21(2):81-6 [11007659.001]

[Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]

[Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]

[Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]

[Cites] J Clin Oncol. 2004 Aug 15;22(16):3395-407 [15199087.001]

[Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]

[Cites] Intern Med J. 2004 Aug;34(8):492-500 [15317548.001]

[Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]

[Cites] CMAJ. 1993 Feb 15;148(4):507-12 [8431814.001]

[Cites] N Engl J Med. 1993 May 13;328(19):1365-71 [8474513.001]

[Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]

[Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]

[Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1369-72 [7577053.001]

[Cites] Nat Med. 1995 Apr;1(4):348-52 [7585065.001]

[Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]

[Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]

[Cites] Med Care Res Rev. 2004 Dec;61(4):453-73 [15536209.001]

[Cites] Health Aff (Millwood). 2005 Jan-Feb;24(1):18-28 [15647212.001]

[Cites] Cancer. 2005 Apr 25;105(2):101-9 [15643601.001]

[Cites] Eval Health Prof. 2006 Mar;29(1):65-88 [16510880.001]

[Cites] Qual Health Care. 1999 Sep;8(3):177-83 [10847875.001]

(PMID = 19399202.001).

[ISSN] 1488-2310

[Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie

[ISO-abbreviation] Can J Surg

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Canada

[Other-IDs] NLM/ PMC2663496

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients.

Two recent North American studies have shown that completion of 5-fluorouracil (5FU)-based adjuvant chemotherapy is a major prognostic factor for the survival of elderly stage III colon cancer patients.

The study cohort comprised 851 stage III colon cancer patients treated by surgery alone and 461 who initiated the Mayo chemotherapy regime.

The current and previous studies demonstrate the importance of completing adjuvant 5-FU-based chemotherapy for colon cancer.

[MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colonic Neoplasms / drug therapy. Colonic Neoplasms / mortality

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. FLUOROURACIL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2002 Sep 1;20(17):3605-16 [12202661.001]

[Cites] J Clin Oncol. 2002 Mar 15;20(6):1491-8 [11896096.001]

[Cites] J Clin Oncol. 2002 Oct 1;20(19):3992-8 [12351596.001]

[Cites] Br J Cancer. 2003 May 19;88(10):1510-5 [12771914.001]

[Cites] Br J Cancer. 2003 Jun 16;88(12):1859-65 [12799627.001]

[Cites] J Clin Oncol. 2003 Aug 1;21(15):2896-903 [12885807.001]

[Cites] Clin Cancer Res. 2003 Aug 1;9(8):2898-903 [12912934.001]

[Cites] J Clin Oncol. 2003 Oct 15;21(20):3729-36 [14551292.001]

[Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5860-5 [14676107.001]

[Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]

[Cites] Oncology (Williston Park). 2004 May;18(6):751-5; discussion 755-8 [15214594.001]

[Cites] Eur J Cancer. 2004 Oct;40(15):2230-6 [15454247.001]

[Cites] J Clin Oncol. 1988 Oct;6(10):1653-64 [3049954.001]

[Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]

[Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]

[Cites] J Clin Oncol. 1992 Jul;10(7):1171-5 [1607921.001]

[Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]

[Cites] J Clin Oncol. 1994 Jun;12(6):1291-5 [8201391.001]

[Cites] J Clin Oncol. 1997 Jan;15(1):246-50 [8996149.001]

[Cites] J Clin Oncol. 1998 Nov;16(11):3537-41 [9817272.001]

[Cites] Eur J Cancer. 1998 Nov;34(12):1871-5 [10023308.001]

[Cites] Cancer. 2005 Mar 15;103(6):1165-71 [15693031.001]

[Cites] J Clin Oncol. 2005 Mar 20;23(9):1819-25 [15774775.001]

[Cites] N Engl J Med. 2005 Jun 30;352(26):2696-704 [15987918.001]

[Cites] N Engl J Med. 2005 Jun 30;352(26):2746-8 [15987925.001]

[Cites] JAMA. 2005 Dec 7;294(21):2703-11 [16333005.001]

[Cites] Dig Surg. 2005;22(6):401-14 [16479107.001]

[Cites] J Natl Cancer Inst. 2006 May 3;98(9):610-9 [16670386.001]

[Cites] J Clin Oncol. 2006 May 20;24(15):2368-75 [16618946.001]

[Cites] J Clin Oncol. 2007 Jan 1;25(1):102-9 [17194911.001]

[Cites] J Clin Oncol. 1999 Aug;17(8):2412-8 [10561304.001]

[Cites] Br J Cancer. 2001 Mar 2;84(5):600-3 [11237378.001]

[Cites] Ann Intern Med. 2002 Mar 5;136(5):349-57 [11874307.001]

[Cites] J Clin Oncol. 2002 Sep 1;20(17):3617-27 [12202662.001]

(PMID = 17299387.001).

[ISSN] 0007-0920

[Journal-full-title] British journal of cancer

[ISO-abbreviation] Br. J. Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil

[Other-IDs] NLM/ PMC2360063

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A population-based study of adjuvant chemotherapy for stage-II and -III colon cancers.

BACKGROUND: Although clinical trials have demonstrated that adjuvant chemotherapy improves survival for stage-III colon cancer, the benefits remain controversial for stage-II lesions.

The objective of the present study was to determine the extent to which adjuvant chemotherapy is used for patients with stage-II and -III colon cancers.

METHODS: The study population comprised 1074 patients with stage-II and -III colon cancers diagnosed in 2000 in 12 French administrative districts and recorded in population-based cancer registries.

RESULTS: Overall, 20.4% of patients with stage II and 61.9% with stage III received adjuvant chemotherapy.

Among stage-II patients, those receiving chemotherapy decreased from 57.6% in patients aged <or=50 years to 1.1% in those aged >or=85.

The corresponding percentages with stage III were 93.6% and 1.4%.

In multivariate analyses, other factors found to be independently and significantly associated with administration of adjuvant chemotherapy for stage II were extension of the cancer (stage IIA vs. stage IIB), clinical presentation (obstruction or perforation vs. uncomplicated cancer) and discussion of the case at a multidisciplinary case-review meeting.

For stage III, apart from age, discussion of the case at a multidisciplinary meeting was the only factor independently associated with administration of chemotherapy.

CONCLUSION: Adjuvant chemotherapy for stage-III colon cancer is used extensively for patients under 75 years of age.

On the other hand, a substantial percentage of stage-II colon cancer patients receive adjuvant chemotherapy despite its uncertain benefits.

[MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.

(PMID = 20079591.001).

[ISSN] 0399-8320

[Journal-full-title] Gastroentérologie clinique et biologique

[ISO-abbreviation] Gastroenterol. Clin. Biol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] France

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Metastatic lymph node ratio is a more precise predictor of prognosis than number of lymph node metastases in stage III colon cancer.

OBJECTIVE: The objective of this study is to assess the value of metastatic lymph node ratio (LNR) in predicting disease-free survival (DFS) in patients with stage III adenocarcinoma of the colon.

MATERIALS AND METHODS: From 1995 to 2003 inclusively, a total of 624 patients featuring stage III adenocarcinoma of the colon underwent curative resection.

In T3/4LNR1 patients (n = 411), there was no difference in survival between those with N1 stage and those with N2 stage.

Cox proportional hazards regression analysis revealed that N stage (number of positive lymph nodes) was not a significant factor when LNR was taken into consideration.

CONCLUSIONS: LNR is a more precise predictor of 5-year DFS than number of positive lymph nodes (N stage) in patients with stage III colon cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Am J Clin Oncol. 2004 Jun;27(3):304-6 [15170153.001]

[Cites] J Gastrointest Surg. 2002 Nov-Dec;6(6):883-88; discussion 889-90 [12504228.001]

[Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):27-34 [11829427.001]

[Cites] Eur J Cancer. 2005 Jan;41(2):272-9 [15661553.001]

[Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):433-41 [17374833.001]

[Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]

[Cites] Gut. 2006 Nov;55(11):1681 [17047131.001]

[Cites] Ann Surg Oncol. 2007 May;14(5):1712-7 [17253102.001]

[Cites] Eur J Surg Oncol. 2005 Feb;31(1):59-66 [15642427.001]

[Cites] Breast Cancer Res. 2004;6(6):R680-8 [15535850.001]

[Cites] Am J Surg. 2007 Dec;194(6):827-31; discussion 831-2 [18005779.001]

[Cites] Eur J Surg Oncol. 2008 Jul;34(7):771-5 [18079086.001]

[Cites] J Clin Oncol. 2005 Dec 1;23(34):8706-12 [16314630.001]

[Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71 [12513963.001]

[Cites] Ann Surg Oncol. 2008 Jun;15(6):1600-8 [18327530.001]

[Cites] Ann Surg. 2002 Apr;235(4):458-63 [11923600.001]

[Cites] Am J Surg Pathol. 2002 Feb;26(2):179-89 [11812939.001]

[Cites] Am Surg. 2004 Mar;70(3):235-40; discussion 240 [15055847.001]

[Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]

[Cites] Cancer. 1967 Nov;20(11):1976-85 [6061631.001]

[Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):219-25 [15687365.001]

(PMID = 19479270.001).

[ISSN] 1432-1262

[Journal-full-title] International journal of colorectal disease

[ISO-abbreviation] Int J Colorectal Dis

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Long-term results after surgery for colorectal adenocarcinoma, stage I-III. Problems of prognosis].

[Transliterated title] Rezultate la distanţă după tratamentul chirurgical al adenocarcinomului colo-rectal stadiile I-III. Probleme de prognostic.

STUDY DESIGN: Prospective study on 142 consecutively cases with stage I to III colorectal adenocarcinomas (TNM AJCC/UICC) in which patients underwent potentially curative surgery in one single public health service (1st Surgical Clinic Iaşi, Romania) between 2004 and 2005.

The surgical procedures performed were the following: right colectomy (n = 54; 30%); transverse colectomy (n = 2; 1.4%); left colectomy (n = 19; 13.4%); segmental colon resection with anastomosis (n = 5 ; 3.5%); Hartmann procedure (n = 18; 12.7%); anterior rectal resection (n = 11; 7.7%) and abdominoperineal resection (n = 33; 23.2%).

RESULTS: The factors with a significant negative influence in overall survival and 42-months survival rates were: the age over 70 years, the emergency surgery related to cancer's complications, the advanced AJCC/ UICC stage, vascular invasion, perineural invasion, the recurrence of disease, the moderate and lower differentiated adenocarcinoma and incomplete or not performed chemotherapy.

CONCLUSION: Even with a radical surgical approach the advanced stage of colorectal adenocarcinoma has a low prognostic, but some other factors have also a high significance in postoperative outcome.

[MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Colectomy / methods. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18389783.001).

[ISSN] 0048-7848

[Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i

[ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi

[Language] rum

[Publication-type] English Abstract; Journal Article

[Publication-country] Romania

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Lymph node ratio as prognosis factor for colon cancer treated by colorectal surgeons.

PURPOSE: This study was designed to assess the prognostic value of the lymph node ratio in patients with colon cancer treated by colorectal specialists.

METHODS: Three hundred and sixty-two Stage III consecutive cases were analyzed based on quartiles: lymph node ratio 1 (>0 and <0.06); lymph node ratio 2 (between 0.06 and 0.12); lymph node ratio 3 (>0.12 and <0.25); lymph node ratio 4 (>or=0.25).

CONCLUSION: A lymph node ratio >or=0.25 was an independent prognostic factor in Stage III colon adenocarcinoma regardless of the number positive nodes.

[MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Lymph Node Excision. Lymph Nodes / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19571700.001).

[ISSN] 1530-0358

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer.

PURPOSE: This study was designed to investigate whether the histologic types of the primary lesion and of metastatic lymph nodes in Stage III colon cancer are useful as prognostic factors.

METHODS: Stage III colon cancer patients were enrolled and were divided into two groups: Group W, in which the histologic type of both primary tumors and metastatic lymph nodes was well-differentiated adenocarcinoma; and Group U, in which the primary tumors and the metastatic lymph nodes were of any type other than well-differentiated.

CONCLUSIONS: In Stage III colon cancer, the prognosis of cases whose primary lesion and lymph node tissues are both well differentiated is extremely good.

[MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology

Genetic Alliance. consumer health - Metastatic cancer.

Hazardous Substances Data Bank. MITOMYCIN C .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16625329.001).

[ISSN] 0012-3706

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial

[Publication-country] United States

[Chemical-registry-number] 0 / Alkylating Agents; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Genetic disregulation of TNF alpha and TNF alpha type II receptors in colon cancer at the II and III stage of disease.

The expression of the genes coding TNFalpha and TNF RII receptors (TNF RII: TNFR2 membrane and soluble domain, TNFR2/R7 soluble domain) was analysed in colon cancer at the II and III stage of disease, by estimation of mRNA expression.

The study included 80 patients with histopathologically confirmed adenocarcinoma.

The highest number of mRNA TNF-alpha copies were investigated in all samples of tissue and independently of the stage of disease.

Simultaneously, we noticed the largest number of mRNA copies for TNFalpha and TNF R2/R7 in healthy cells at stage III of the disease.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18088549.001).

[ISSN] 0393-974X

[Journal-full-title] Journal of biological regulators and homeostatic agents

[ISO-abbreviation] J. Biol. Regul. Homeost. Agents

[Language] eng

[Publication-type] Journal Article

[Publication-country] Italy

[Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Tumor Necrosis Factor, Type II; 0 / Tumor Necrosis Factor-alpha

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: 4596 Background: Small bowel adenocarcinoma is a rare malignancy and is often associated with poor outcome.

METHODS: Patients aged 18-90 with adenocarcinoma of the small intestine diagnosed between 1988 and 2005 were identified from SEER data (ver. 2008).

Cox proportional hazards regression analyses were performed after adjusting for age, sex, race, T stage, grade, and primary site.

Stage I-II cases were categorized by total LN examined (1-8, 9-12, and >12).

Stage III cases were evaluated using cut-point analysis to determine the number of positive LN that predicted outcomes.

Survival among stage I/II patients (n=1,216) was dependent upon the total number of LN assessed.

5-year DSS for stage II patients was 66%, 82% (HR 0.52 95% CI .33-.84), and 88% (HR 0.38, 95% CI .23-.61) for 1-8, 9-12, >12 LN, respectively.

The optimal cutpoint of positive LN for stage III disease (n=775) was <3 compard to ≥3 with 5 year DSS of 58% vs. 37% (HR 1.49, 95% CI 1.15-1.92, P=0.002), respectively.

Among stage III patients, the LNR was even more predictive of survival than stratification by the number of positive lymph nodes as demonstrated by an improved chi-square statistic for the multivariate model (78.8 vs 63.1, P=0.0005).

CONCLUSIONS: As noted in colon cancer, the total number of LN assessed has considerable influence upon survival in stage I, II and III small bowel adenocarcinoma.

Stratifying stage III small bowel adenocarcinoma into those with <3 and ≥3 positive lymph nodes significantly improves prognostication for these patients and future staging systems should incorporate the number of positive nodes into nodal staging.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963112.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Does delay of adjuvant chemotherapy affect the clinical outcome in patients with colon cancer?

: 4046 Background: Adjuvant chemotherapy (AC) in patients with stage III colon adenocarcinoma prevents recurrences and improves survival.

We hypothesized that AC commenced within 60 days of resection would increase survival in patients with stage II and III colon cancer.

METHODS: Patients with newly diagnosed stage II or III colon adenocarcinoma who received fluoropyrimidine based AC in two centers (a private cancer center and a large community hospital) between 2000 and 2007 were included into analysis.

116 patients (61%) were female and 35 patients (18%) had stage II disease.

The only difference between the two groups was the higher N stage in group 1.

The treating hospital and the N stage were found to be the factors affecting the OS in univariate analysis.

CONCLUSIONS: Delay of AC more than 60 days after resection is associated with inferior survival in stage II/III colon cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961564.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The primary tumor site was 21.9% (32) right colon, 5.5% (8) transverse colon, 45.2% (66) left colon and 27.4%(40) rectal cancer.

Adenocarcinoma was the unique histotype and mucinous differentiation was observed in 14.7% (21).

The Pathological Stage at diagnosis was Stage I 3.42% (5), II 24% (35), III 33.6% (49) and IV 39% (57).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963599.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: Three hundred and ninety- seven consecutive patients with curatively resected colorectal adenocarcinoma were enrolled in the present study.

RESULTS: The median age of the patients was 63 years (range, 21-85), and 218 (54.9%) patients had colon cancer and 179 (45.1%) patients rectal cancer.

Pathologic stages after surgery were as follows: stage 0/I (n=86, 21.7%), stage II (n=146, 36.8%), stage III (n=145, 36.5%), and stage IV (n=20, 5.0%).

Multivariate survival analysis including stage, differentiation, age, and CEA level showed that the survival for the patients with the -93AA genotype of hMLH1 was worse than for the patients with the combined -93GG and GA genotype (overall survival: hazard ratio [HR]=2.953, 95% Confidential Interval [CI], 1.273-6.850, P=0.012; disease-free survival: HR=2.299, 95% CI, 1.417-3.730, P=0.001), whereas the other polymorphisms were not associated with survival.

Accordingly, in addition to the pathologic stage, the analysis of -93G>A polymorphism of hMLH1 can help identify patient subgroups at high risk of a poor disease outcome.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961540.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Metastasis of colonic adenocarcinoma to the external ear canal: an unusual case with a complex-pattern of disease progression.

We report on a patient who developed far-ranging metastases of adenocarcinoma of the colon that followed a gradual cephalad progression, including the right external ear canal, and led to hearing loss.

The patient was a 63-year-old white male with stage III adenocarcinoma of the colon.

Physical examination of the head and neck showed a mass in the external ear canal, and biopsy confirmed adenocarcinoma.

The significance of such wide-ranging metastases is that metastasis of adenocarcinoma to the ear did not signal imminent death, and relief of the hearing loss it caused was possible.

[MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Ear Canal. Ear Neoplasms / secondary

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15742771.001).

[ISSN] 0145-5613

[Journal-full-title] Ear, nose, & throat journal

[ISO-abbreviation] Ear Nose Throat J

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic indicators for stage II (Dukes' stage B) adenocarcinoma of the colon.

To determine the prognostic indicators that are associated with lower disease free survival (DFS) and overall survival (OS) in stage II colon cancer patients, the tumor registry records were reviewed for all patients diagnosed with stage II and III adenocarcinoma of the colon at Charleston Area Medical Center from 1986 to 1994.

The prognostic indicators of 174 stage II patients who had not undergone treatment were assessed for DFS and OS.

In addition, DFS and OS curves for stage II patients with < 7 LNR were not significantly different from survival curves for stage III patients.

Treatment decisions are made based primarily on stage, and stage II patients are not routinely offered adjuvant therapy.

[MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Neoplasm Staging. Survival Analysis

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16422269.001).

[ISSN] 0043-3284

[Journal-full-title] The West Virginia medical journal

[ISO-abbreviation] W V Med J

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Adjuvant chemotherapy in elderly patients (>or=75 yr) completely resected for colon cancer stage III compared to younger patients: toxicity and prognosis.

PURPOSE: To compare benefits and risks to adjuvant chemotherapy following complete resection of node-positive colon cancer stage III for patients aged >or=75 yr and younger.

CONCLUSIONS: Adjuvant 5-FU chemotherapy should be considered for elderly patients aged >or=75 yr in good performance at high risk of recurrence of colon carcinoma after resection.

[MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colonic Neoplasms / drug therapy

Hazardous Substances Data Bank. FLUOROURACIL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2002 Oct 1;20(19):3992-8 [12351596.001]

[Cites] Ann Intern Med. 2002 Mar 5;136(5):349-57 [11874307.001]

[Cites] Cancer Control. 1995 Mar;2(2 Suppl 1):36-38 [10887408.001]

[Cites] Pharmacol Rev. 2004 Jun;56(2):163-84 [15169926.001]

[Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):850-7 [11390534.001]

[Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]

[Cites] Gastroenterology. 1994 Apr;106(4):899-906 [8143995.001]

[Cites] Lancet. 1999 Jan 30;353(9150):391-9 [9950460.001]

[Cites] Cancer. 2002 Apr 1;94(7):1931-8 [11932894.001]

[Cites] Lancet. 2000 May 6;355(9215):1588-96 [10821362.001]

[Cites] J Clin Oncol. 1999 Aug;17(8):2412-8 [10561304.001]

[Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]

[Cites] Ann Oncol. 2004 Apr;15(4):568-73 [15033660.001]

[Cites] J Clin Oncol. 2003 Aug 1;21(15):2896-903 [12885807.001]

[Cites] Am J Clin Oncol. 2003 Feb;26(1):103-6 [12576935.001]

[Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]

[Cites] Ann Oncol. 2005 May;16(5):767-72 [15817594.001]

[Cites] N Engl J Med. 1999 Dec 30;341(27):2061-7 [10615079.001]

[Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]

[Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]

[Cites] Cancer J. 2001 May-Jun;7(3):213-8 [11419029.001]

[Cites] Lancet. 1995 Apr 15;345(8955):939-44 [7715291.001]

[Cites] J Clin Oncol. 1989 Oct;7(10):1447-56 [2778478.001]

[Cites] Am J Clin Oncol. 1982 Apr;5(2):227-36 [7091044.001]

[Cites] Ann Oncol. 2000 Aug;11(8):947-55 [11038030.001]

[Cites] J Clin Oncol. 1984 Jul;2(7):849-55 [6737023.001]

[Cites] J Clin Oncol. 1998 Jan;16(1):295-300 [9440756.001]

[Cites] J Clin Oncol. 1999 Nov;17(11):3553-9 [10550154.001]

[Cites] Cancer. 1995 Feb 1;75(3):775-81 [7828127.001]

[Cites] Cancer. 1996 Aug 15;78(4):918-26 [8756390.001]

[Cites] Lancet. 2000 May 20;355(9217):1745-50 [10832824.001]

[Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]

(PMID = 17303911.001).

[ISSN] 1357-0560

[Journal-full-title] Medical oncology (Northwood, London, England)

[ISO-abbreviation] Med. Oncol.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.

BACKGROUND: The aim was to determine the values of p53 tumour expression and microsatellite instability (MSI) phenotype to predict benefit from adjuvant chemotherapy of colon cancer by 5-fluorouracil and leucovorin (FL) alone or with oxaliplatin (FOLFOX).

PATIENTS AND METHODS: This retrospective study included 233 unselected patients with stage III colon cancer treated by FL (n = 124) or FOLFOX (n = 109).

CONCLUSION: Our observations indicate that MSI status and p53 expression may influence the impact of oxaliplatin on adjuvant treatment of stage III colon cancer patients.

Hazardous Substances Data Bank. FLUOROURACIL .

Hazardous Substances Data Bank. LEUCOVORIN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19833818.001).

[ISSN] 1569-8041

[Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology

[ISO-abbreviation] Ann. Oncol.

[Language] ENG

[Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Tumor Suppressor Protein p53; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.

PURPOSE: In 1990, fluorouracil (FU) plus levamisole for 1 year became standard adjuvant treatment for patients with high-risk stages II and III colon cancer.

INT-0089 has long-term follow-up of the largest clinical trial of patients with high-risk colon cancer, documenting not only the durability of the treatment effects, but also the natural history of patients with high-risk colon cancer, and analyses of treatment based on age, race, and comorbid conditions such as obesity, diabetes, and second primary cancers.

[MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. FLUOROURACIL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16314627.001).

[ISSN] 0732-183X

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA15488; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA66636

[Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Adjuvants, Immunologic; 12001-76-2 / Vitamin B Complex; 2880D3468G / Levamisole; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.

BACKGROUND: The recommendation of adjuvant chemotherapy for colon cancer with lymph node metastases, based on two studies from USA, was reluctantly accepted by Norwegian medical doctors.

MATERIAL AND METHODS: Four hundred and twenty five patients with operable colon and rectum cancer, Stage II and III (Dukes' stage B and C), were from January 1993 to October 1996, included in a randomised multicentre trial in Norway.

There was no difference between the two groups when analysed for colon and rectum separately.

However, the subgroup of colon cancer with stage III exhibited a statistically significant difference both for DFS, 58% vs. 37% (p=0.012) and CSS, 65% vs. 47% (p=0.032) in favour of adjuvant chemotherapy.

CONCLUSIONS: Colon cancer patients with lymph node metastases benefit from adjuvant chemotherapy with 5-FU/Lev with acceptable toxicity.

[MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Antirheumatic Agents / therapeutic use. Colonic Neoplasms / drug therapy. Fluorouracil / therapeutic use. Levamisole / therapeutic use. Rectal Neoplasms / drug therapy

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19242829.001).

[ISSN] 1651-226X

[Journal-full-title] Acta oncologica (Stockholm, Sweden)

[ISO-abbreviation] Acta Oncol

[Language] eng

[Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

[Publication-country] Norway

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antirheumatic Agents; 2880D3468G / Levamisole; U3P01618RT / Fluorouracil

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Laparoscopic colectomy for colon adenocarcinoma: an 11-year retrospective review with 5-year survival rates.

BACKGROUND: Laparoscopic colectomy for the management of colon cancer remains a controversial therapeutic option, especially when the outcomes are compared with the historically accepted survival data and recurrence rates after open surgery.

The purpose of this study was to evaluate the 5-year overall and disease-free survival rates after laparoscopic colon resection for invasive colon adenocarcinoma.

METHODS: A total of 129 patients underwent consecutive laparoscopic colectomies for colon adenocarcinoma (between April 1992 and 2004 January) by a single surgeon at a single institution.

RESULTS: After patients with noninvasive disease on final pathology were excluded, the study population comprised 88 patients who underwent laparoscopic colectomies for invasive colon cancer with > 2 years of follow-up.

The Kaplan-Meier survival data were as follows for 5-year overall survival and 5-year disease-free survival, respectively stage I (n = 34) 89% and 89%; stage II (n = 22), 65% and 59%; stage III (n = 19), 72% and 67%; stages I-III combined, (n = 75), 77% and 73%.

CONCLUSIONS: For this specific cohort of patients undergoing curative laparoscopic colectomies for invasive colon adenocarcinoma, the mean follow-up was > 5 years.

Overall survival and disease-free survival for stage I, II, and III colon cancer as well as for stages I-III combined are favorable and comparable to historically acceptable open colectomy survival rates.

Overall survival and disease-free survival after laparoscopic colectomy for invasive colon cancer is no worse, and perhaps better than, the previously reported rates for the same procedure done by an open technique.

[MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery. Laparoscopy / methods

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Surg Endosc. 2006 Jun;20(6):996-7 [16739001.001]

[Cites] Br J Surg. 1995 Mar;82(3):295-8 [7795990.001]

[Cites] World J Surg. 1993 Jan-Feb;17(1):51-6 [8447141.001]

[Cites] Dis Colon Rectum. 1996 Oct;39(10 Suppl):S53-8 [8831547.001]

[Cites] Dis Colon Rectum. 1996 Oct;39(10 Suppl):S20-3 [8831542.001]

[Cites] Dis Colon Rectum. 1996 Feb;39(2):155-9 [8620781.001]

[Cites] J Surg Oncol. 1998 Aug;68(4):255-67 [9721713.001]

[Cites] Dis Colon Rectum. 1983 Sep;26(9):571-2 [6223795.001]

[Cites] Dis Colon Rectum. 2003 May;46(5):601-11 [12792435.001]

[Cites] Ann Surg. 2002 Dec;236(6):759-66; disscussion 767 [12454514.001]

[Cites] Surg Endosc. 1996 Nov;10(11):1041-4 [8881048.001]

[Cites] Ann Surg. 1992 Dec;216(6):703-7 [1466626.001]

[Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]

[Cites] Dis Colon Rectum. 1996 Oct;39(10 Suppl):S35-46 [8831545.001]

[Cites] Dis Colon Rectum. 1996 Feb;39(2):148-54 [8620780.001]

[Cites] Dis Colon Rectum. 1996 Feb;39(2):200-7 [8620788.001]

[Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]

[Cites] Ann Surg. 2001 Nov;234(5):590-606 [11685021.001]

[Cites] Surg Endosc. 2002 Oct;16(10):1409-12 [12140622.001]

[Cites] Surg Oncol. 2000 Nov;9(3):127-34 [11356341.001]

(PMID = 15789256.001).

[ISSN] 1432-2218

[Journal-full-title] Surgical endoscopy

[ISO-abbreviation] Surg Endosc

[Language] eng

[Publication-type] Comparative Study; Evaluation Studies; Journal Article

[Publication-country] Germany

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.

The purpose of this trial was to investigate the efficacy of adjuvant chemotherapy with 5-fluorouracil (5-FU) and leucovorin (LV) in stage II colon cancer.

Patients with stage II colon cancer were randomised to either adjuvant chemotherapy with 5-FU/LV (100 mg m(-2) LV+450 mg m(-2) 5-FU weekly, weeks 1-6, in 8 weeks cycles x 7) or surveillance only.

In conclusion, results of this trial demonstrate a trend to a lower risk for relapse in patients treated with adjuvant 5-FU/LV for stage II colon cancer.

[MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Neoplasm Recurrence, Local / prevention & control

Hazardous Substances Data Bank. FLUOROURACIL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 1999 Nov;17(11):3553-9 [10550154.001]

[Cites] Ann Surg. 2006 Oct;244(4):602-10 [16998369.001]

[Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]

[Cites] J Clin Oncol. 2003 Aug 1;21(15):2912-9 [12885809.001]

[Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]

[Cites] J Clin Oncol. 2004 Aug 15;22(16):3395-407 [15199087.001]

[Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]

[Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]

[Cites] Biometrics. 1975 Mar;31(1):103-15 [1100130.001]

[Cites] J Natl Cancer Inst. 1988 Mar 2;80(1):30-6 [3276901.001]

[Cites] Arch Surg. 1989 Feb;124(2):180-2 [2916939.001]

[Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]

[Cites] J Clin Oncol. 1990 Sep;8(9):1466-75 [2202789.001]

[Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]

[Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]

[Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]

[Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]

[Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]

(PMID = 17895886.001).

[ISSN] 0007-0920

[Journal-full-title] British journal of cancer

[ISO-abbreviation] Br. J. Cancer

[Language] eng

[Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial

[Publication-country] England

[Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil

[Other-IDs] NLM/ PMC2360441

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

We took advantage of PETACC-3, an adjuvant trial with 3,278 patients with stage II to III colon cancer, to evaluate the prognostic value of KRAS and BRAF tumor mutation status in this setting.

RESULTS: KRAS and BRAF tumor mutation rates were 37.0% and 7.9%, respectively, and were not significantly different according to tumor stage.

In a multivariate analysis containing stage, tumor site, nodal status, sex, age, grade, and microsatellite instability (MSI) status, KRAS mutation was associated with grade (P = .0016), while BRAF mutation was significantly associated with female sex (P = .017), and highly significantly associated with right-sided tumors, older age, high grade, and MSI-high tumors (all P < 10(-4)).

CONCLUSION: In stage II-III colon cancer, the KRAS mutation status does not have major prognostic value.

[MeSH-major] Adenocarcinoma / genetics. Colonic Neoplasms / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins B-raf / genetics. ras Proteins / genetics

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20008640.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Sentinel lymph node mapping for adenocarcinoma of the colon does not improve staging accuracy.

PURPOSE: This study was designed to: determine the efficacy of sentinel lymph node mapping in patients with intraperitoneal colon cancer; and create an algorithm to predict potential survival benefit by using best-case estimates in favor of sentinel node mapping and lymph node ultraprocessing techniques.

METHODS: Forty-one patients with intraperitoneal colon cancer undergoing colectomy with curative intent were studied prospectively.

After mobilization of the colon and mesentery, 1 to 2 ml of isosulfan blue dye was injected subserosally around the tumor.

Stage of disease in the remaining 38 patients was: I, n = 10 (26 percent); II, n = 15 (39 percent); III, n = 11 (29 percent); IV, n = 2 (5 percent).

To create a survival benefit algorithm, we assumed the following: combined fraction of Stage I and II disease (0.5); fraction understaged by bivalving and hematoxylin and eosin staining that would have occult positive nodes by more sophisticated analysis (0.15); fraction of occult positive nodes detected by sentinel node mapping (0.9); and survival benefit from chemotherapy (0.33).

CONCLUSIONS: Sentinel node mapping with isosulfan blue dye and routine processing of retrieved nodes does not improve staging accuracy in patients with intraperitoneal colon cancer.

[MeSH-major] Adenocarcinoma / pathology. Algorithms. Colonic Neoplasms / pathology. Neoplasm Staging / methods. Sentinel Lymph Node Biopsy

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15690662.001).

[ISSN] 0012-3706

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Clinical Trial; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis.

BACKGROUND: Cases of severe gastrointestinal toxicity were monitored prospectively during NSABP C-07, a randomized clinical trial of adjuvant therapy for patients with stage II/III colon cancer.

[MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colonic Diseases / chemically induced. Colonic Neoplasms / drug therapy

MedlinePlus Health Information. consumer health - Colonic Diseases.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. FLUOROURACIL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17853393.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Databank-accession-numbers] ClinicalTrials.gov/ NCT00004931

[Grant] United States / NCI NIH HHS / CA / U10-CA-12027; United States / NCI NIH HHS / CA / U10-CA-37377; United States / NCI NIH HHS / CA / U10-CA-69651; United States / NCI NIH HHS / CA / U10-CA-69974

[Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Transforming growth factor-beta1 (TGF-beta1) and acetylcholine (ACh) alter nitric oxide (NO) and interleukin-1beta (IL-1beta) secretion in human colon adenocarcinoma cells.

Colon adenocarcinoma is one of the most common fatal malignancies in Western countries.

The present study was conducted to assess the influence of recombinant human transforming growth factor (rhTGF)-beta1 or ACh on nitric oxide (NO) and interleukin-1beta (IL-1beta) secretion by three human colon adenocarcinoma cell lines: HT29, LS180, and SW948, derived from different grade tumors (Duke's stage).

Colon carcinoma cells exhibited different sensitivities to rhTGF-beta1 or ACh dependent on the tumor grade and the culture model.

ACh exhibited significant inhibitory effects towards NO, endothelial nitric oxide synthase (eNOS), and IL-1beta secretion especially by tumor cells derived form Duke's C stage of colon carcinoma. rhTGF-beta1 also decreased NO, IL-1beta, and eNOS expression, but its effect was lower than that observed after the administration of ACh.

Taken together, the TGF-beta1-ACh axis may regulate colon carcinoma progression and metastasis by altering NO secretion and influence inflammatory responses by modulating IL-1beta production.

[MeSH-minor] Cell Line, Tumor. Enzyme-Linked Immunosorbent Assay. Humans. Nitric Oxide Synthase Type III / metabolism

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Int J Biol Markers. 2005 Oct-Dec;20(4):235-41 [16398405.001]

[Cites] Gastroenterology. 1996 Feb;110(2):375-82 [8566583.001]

[Cites] Cell Biol Int. 2005 Jul;29(7):497-505 [15893483.001]

[Cites] World J Surg. 2005 Mar;29(3):306-11 [15711891.001]

[Cites] Cancer Metastasis Rev. 2006 Sep;25(3):387-408 [17043764.001]

[Cites] Baillieres Clin Haematol. 1992 Jul;5(3):703-21 [1333850.001]

[Cites] Med Hypotheses. 2008;70(1):43-51 [17587508.001]

[Cites] Clin Immunol. 2002 Feb;102(2):169-78 [11846459.001]

[Cites] Biochem Pharmacol. 2004 Jun 15;67(12):2197-205 [15163551.001]

[Cites] Cancer Res. 2003 Oct 15;63(20):6744-50 [14583469.001]

[Cites] J Am Coll Cardiol. 1997 Feb;29(2):308-17 [9014982.001]

[Cites] Br J Cancer. 1996 Dec;74(12):1955-60 [8980396.001]

[Cites] Eur J Cancer. 2000 Jun;36(10):1288-91 [10882868.001]

[Cites] Lancet Oncol. 2001 Mar;2(3):149-56 [11902565.001]

[Cites] Clin Exp Metastasis. 1997 Nov;15(6):557-67 [9344040.001]

[Cites] Dig Dis Sci. 1999 May;44(5):916-21 [10235597.001]

[Cites] J Cancer Res Clin Oncol. 2003 May;129(5):272-8 [12748850.001]

[Cites] Int J Mol Med. 2002 Jun;9(6):651-7 [12011984.001]

[Cites] Eur J Cancer. 2001 Jan;37(2):224-33 [11166150.001]

[Cites] Ann Med. 1995 Jun;27(3):359-67 [7546626.001]

[Cites] Mutat Res. 2004 Nov 2;555(1-2):107-19 [15476855.001]

[Cites] Drug Resist Updat. 2006 Jun;9(3):157-73 [16822706.001]

[Cites] Clin Exp Metastasis. 2005;22(4):341-9 [16170670.001]

[Cites] Gastroenterology. 1995 Aug;109(2):483-9 [7615197.001]

[Cites] Med Hypotheses. 2007;69(6):1272-6 [17553629.001]

[Cites] Cancer Immunol Immunother. 2004 Aug;53(8):723-8 [15034673.001]

[Cites] Inflamm Res. 2004 Feb;53(2):60-5 [15021970.001]

[Cites] Life Sci. 2003 Mar 28;72(18-19):2159-68 [12628474.001]

[Cites] J Transl Med. 2006 Nov 10;4:48 [17096856.001]

(PMID = 19551451.001).

[ISSN] 1543-706X

[Journal-full-title] In vitro cellular & developmental biology. Animal

[ISO-abbreviation] In Vitro Cell. Dev. Biol. Anim.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Interleukin-1beta; 0 / Transforming Growth Factor beta1; 31C4KY9ESH / Nitric Oxide; EC 1.14.13.39 / Nitric Oxide Synthase Type III; N9YNS0M02X / Acetylcholine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Carcinoma obstruction of the proximal colon cancer and long-term prognosis--obstruction is a predictor of worse outcome in TNM stage II tumor.

PURPOSE: Colon obstruction is suggested to be a predictor of poor outcome in colon cancer.

However, the effect of obstruction on outcome in patients with different tumor-nodes-metastases (TNM) stage cancer has not been fully addressed.

The aim of this study is to determine whether colon obstruction predicts surgical and long-term oncologic outcomes in patients with proximal colon cancer.

METHODS: A total of 1,492 consecutive patients underwent open resection of primary adenocarcinoma of right colon in a single institution between January 1995 and December 2005.

Univariate and multivariate analyses were performed to identify colon obstruction and other predictors of surgical and oncologic outcomes.

RESULTS: Among 1,492 patients, 306 (20.5%) patients presented with colon obstruction.

Obstruction predicted a worse long-term disease-free survival (DFS) among patients with stage II-III disease (log-rank test, p = 0.0003).

The data were stratified by TNM stage.

Obstruction predicted a worse DFS among patients with TNM stage II cancer (598 patients; log-rank test, p = 0.001; Cox regression, p = 0.012), but it was not a predictor in TNM stage III cancer patients (424 patients; p = 0.116; p = 0.108).

CONCLUSIONS: Colon obstruction was an independent predictor of long-term outcome only in TNM stage II but not in stage III proximal colon cancer.

Patients with TNM stage II obstructive colon cancer could be included in future trials of adjuvant therapies.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Surgery. 2000 Apr;127(4):370-6 [10776426.001]

[Cites] Int J Colorectal Dis. 2009 Jun;24(6):665-76 [19238405.001]

[Cites] Am J Surg. 2004 Apr;187(4):497-500 [15041498.001]

[Cites] Eur J Cancer. 1996 Feb;32A(2):295-302 [8664045.001]

[Cites] Colorectal Dis. 2008 Jan;10(1):33-40 [17672872.001]

[Cites] Ann Surg. 1983 Dec;198(6):743-52 [6357118.001]

[Cites] Hepatogastroenterology. 2008 Jul-Aug;55(85):1288-92 [18795674.001]

[Cites] Br J Surg. 1989 Sep;76(9):965-9 [2804601.001]

[Cites] Br J Surg. 1986 Aug;73(8):663-70 [3742184.001]

[Cites] Rev Med Chil. 2004 Jun;132(6):691-700 [15332370.001]

[Cites] Ann Surg Oncol. 2006 Jun;13(6):887-98 [16614880.001]

[Cites] J Surg Oncol. 1991 Jul;47(3):188-92 [2072703.001]

[Cites] J Clin Oncol. 2004 Aug 15;22(16):3395-407 [15199087.001]

[Cites] Am J Clin Pathol. 2003 Jan;119(1):108-13 [12520705.001]

[Cites] Br J Surg. 2006 Apr;93(4):483-8 [16555262.001]

[Cites] Lancet. 1986 Oct 18;2(8512):904-7 [2876336.001]

[Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]

[Cites] Br Med J. 1979 Sep 1;2(6189):515-7 [497669.001]

[Cites] Br J Surg. 1985 Apr;72(4):296-302 [3986481.001]

[Cites] Dis Colon Rectum. 1991 Sep;34(9):759-62 [1914740.001]

[Cites] Dis Colon Rectum. 1997 Mar;40(3):326-31 [9118749.001]

(PMID = 20135321.001).

[ISSN] 1432-1262

[Journal-full-title] International journal of colorectal disease

[ISO-abbreviation] Int J Colorectal Dis

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Clinical features of colorectal mucinous adenocarcinoma].

OBJECTIVE: To investigate the clinicopathological characteristics and prognosis of colorectal mucinous adenocarcinoma (MAC) and non-mucinous adenocarcinoma (NMAC).

METHODS: Clinical data of 2089 cases with colorectal cancer from 1994 to 2007 in our hospital, including 169 patients diagnosed as mucinous adenocarcinoma were analyzed retrospectively.

The rates of tumor location in colon (97 cases,57.4% vs 814 cases, 44.3%, in MAC and NMAC) were significantly different (P<0.01).

The rate of radical resection (86.4% vs 91.5%), hepatic metastasis (5.3% vs 8.5%) and local recurrence had no significant difference between patients with mucinous and non-mucinous adenocarcinoma (P>0.05).

In comparison to NMAC patients, MAC patients were worse in long-term overall survival, the survival of receiving radical resection and of TNM stage (II+III) group (P<0.01).

Survivals were not significantly different in TNM stage I and IV groups between mucinous and non-mucinous adenocarcinoma (P>0.05).

CONCLUSIONS: Colorectal mucinous adenocarcinoma patients have worse outcome in comparison to non-mucinous adenocarcinoma patients.

Mucinous adenocarcinoma may have special biological behavior, which is an independent prognostic factor for patients with colorectal cancer.

[MeSH-major] Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19742341.001).

[ISSN] 1671-0274

[Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery

[ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Sporadic medullary carcinoma of the colon: a clinicopathologic comparison with nonhereditary poorly differentiated enteric-type adenocarcinoma and neuroendocrine colorectal carcinoma.

We studied 68 sporadic colorectal carcinomas (CRCs) with medullary features (MCRCs) and compared them with 35 poorly differentiated purely "enteric" CRCs (ECRCs) and 15 purely neuroendocrine carcinomas (NECs) of grades II and III, all in patients lacking a family history of CRC.

MCRCs were significantly more common in the ascending colon than were ECRCs, but there was no significant dissimilarity to NECs.

Despite an infiltrative growth pattern, MCRC was less likely than ECRC to manifest with stage III or IV disease, but there was no stage-related difference from NECs.

[MeSH-major] Adenocarcinoma / pathology. Carcinoma, Medullary / pathology. Carcinoma, Neuroendocrine / pathology. Colorectal Neoplasms / pathology

MedlinePlus Health Information. consumer health - Colorectal Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15762280.001).

[ISSN] 0002-9173

[Journal-full-title] American journal of clinical pathology

[ISO-abbreviation] Am. J. Clin. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification?

METHODS: From a prospective database of 496 patients with rectal adenocarcinoma, 107 patients with stage II/III cancers and intermediate response to preoperative 5-FU based RCT (ypT2/3 and TRG 2/3), treated within the German Rectal Cancer Trials were studied.

Furthermore, ypT stage and tumor grading turn out to be additional auxiliary factors.

[MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rectal Neoplasms / pathology. Rectal Neoplasms / therapy

[MeSH-minor] Adult. Aged. Aged, 80 and over. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Preoperative Care. Prospective Studies. Risk Assessment. Survival Rate. Treatment Outcome

Genetic Alliance. consumer health - Rectal Cancer.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2007 Jan 1;25(1):110-7 [17194912.001]

[Cites] J Clin Oncol. 2007 Jun 20;25(18):2573-9 [17577036.001]

[Cites] J Clin Oncol. 2007 Oct 1;25(28):4379-86 [17906203.001]

[Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6617-23 [18006762.001]

[Cites] Dis Colon Rectum. 2008 Mar;51(3):277-83 [18183463.001]

[Cites] Cancer. 2008 Jul 1;113(1):57-64 [18442099.001]

[Cites] J Surg Oncol. 2009 Dec 1;100(7):525-8 [19697351.001]

[Cites] Cancer. 2009 Dec 1;115(23):5432-40 [19673001.001]

[Cites] Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1158-65 [19800178.001]

[Cites] J Clin Oncol. 2001 Jan 1;19(1):157-63 [11134208.001]

[Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]

[Cites] Cancer. 2001 Dec 1;92(11):2754-9 [11753948.001]

[Cites] Arch Surg. 2002 Feb;137(2):206-10 [11822961.001]

[Cites] J Clin Oncol. 2002 Apr 1;20(7):1729-34 [11919228.001]

[Cites] ANZ J Surg. 2002 Jul;72(7):483-7 [12123507.001]

[Cites] Dis Colon Rectum. 2002 Jul;45(7):895-903 [12130878.001]

[Cites] Semin Surg Oncol. 2003;21(1):19-22 [12923912.001]

[Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]

[Cites] Br J Surg. 1982 Oct;69(10):613-6 [6751457.001]

[Cites] N Engl J Med. 1991 Mar 14;324(11):709-15 [1997835.001]

[Cites] Lancet. 1993 Feb 20;341(8843):457-60 [8094488.001]

[Cites] Z Gastroenterol. 2008 Aug;46(8):799-840 [18759205.001]

[Cites] Ann Surg. 2009 Jun;249(6):965-72 [19474683.001]

[Cites] J Surg Oncol. 2009 Oct 1;100(5):387-91 [19582821.001]

[Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]

[Cites] Int J Colorectal Dis. 1997;12(1):19-23 [9112145.001]

[Cites] N Engl J Med. 1997 Jul 31;337(5):346-7; author reply 347-8 [9235500.001]

[Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):935-41 [9869213.001]

[Cites] Dis Colon Rectum. 1999 Feb;42(2):167-73 [10211491.001]

[Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):426-31 [15667963.001]

[Cites] Cancer. 2005 Feb 1;103(3):647-9 [15612025.001]

[Cites] Surg Today. 2005;35(6):442-5 [15912290.001]

[Cites] J Clin Oncol. 2005 Dec 1;23(34):8688-96 [16246976.001]

[Cites] Ann Surg. 2006 Apr;243(4):492-8 [16552200.001]

[Cites] Dis Colon Rectum. 2006 Sep;49(9):1284-92 [16758130.001]

[Cites] J Clin Oncol. 2006 Oct 1;24(28):4620-5 [17008704.001]

(PMID = 20388220.001).

[ISSN] 1477-7819

[Journal-full-title] World journal of surgical oncology

[ISO-abbreviation] World J Surg Oncol

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; U3P01618RT / Fluorouracil

[Other-IDs] NLM/ PMC2864265

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Synchronous colon and gastric advanced carcinomas.

An unusual case of advanced synchronous colon and gastric carcinoma is described.

A 36 year old female was admitted to our Department with a stenosing right colon cancer diagnosed at endoscopy which was performed for lower crampy abdominal pain and gross blood in the stool.

Multiple colon polyps, distal to the tumor, were also detected.

On preoperative abdominal computed tomography, a stenosing right colon cancer, without evidence of abdominal diffusion, was confirmed.

At laparotomy, in addition to colon cancer, an antral gastric cancer was incidentally found.

At histology, a poorly differentiated gastric adenocarcinoma with signet ring-cell component (pT2, pN0; stage IB) and a moderately differentiated colon adenocarcinoma with a tubulovillous component (pT3, pN1; stage III, Stage Dukes C) were revealed.

MedlinePlus Health Information. consumer health - Stomach Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15943046.001).

[ISSN] 0392-9078

[Journal-full-title] Journal of experimental & clinical cancer research : CR

[ISO-abbreviation] J. Exp. Clin. Cancer Res.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Italy

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Survival and prognostic factors of colorectal adenocarcinoma: analytic multifactor review of 150 cases].

[Transliterated title] Survie et facteurs pronostiques des adénocarcinomes colorectaux: étude analytique uni- et multifactorielle de 150 cas.

This study attempts to observe the survival of colorectal adenocarcinoma and to find prognostic factors and other variables potentially associated with outcome of colorectal adenocarcinoma.

MATERIAL AND METHODS: It's a retrospective study based on 150 patients with colorectal adenocarcinoma from 1990 to 2002.

84 patients had colon adenocarcinoma and 66 patients had rectal adenocarcinoma.

In histological exam the adenocarcinoma was well differenced in 69 cases (46%), and undifferentiated in 17 cases (18, 3%).

There were 6 patients (4%) Dukes stage I TNM, 61 stage II (40, 7%), 51 stage III TNM (34%) and 32 patients stage IV TNM (34%).

All patients had surgical curative resection associated with adjuvant chemotherapy in 60 cases of colon adenocarcinoma and preoperative radiotherapy in 33 cases of rectal adenocarcinoma.

In addition to the clinical factors, we found of significant prognostic value undifferentiated adenocarcinoma and an elevated value of serum carcinoembryonic antigen>5 ng/ml.

[MeSH-major] Adenocarcinoma / mortality. Colorectal Neoplasms / mortality

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16443189.001).

[ISSN] 0003-3944

[Journal-full-title] Annales de chirurgie

[ISO-abbreviation] Ann Chir

[Language] fre

[Publication-type] English Abstract; Journal Article

[Publication-country] France

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pathological examination of 12 regional lymph nodes and long-term survival in stages I-III colon cancer patients: an analysis of 2,056 consecutive patients in two branches of same institution.

PURPOSE: Pathologic examination of at least 12 lymph nodes (LNs) is widely accepted as a standard for colon cancer surgery.

METHODS: Patients with stages I-III adenocarcinoma of the colon between 1998 and 2003 were identified from the Chang Gung Colorectal Tumor Registry in two branches (Linkou and Kaohsiung branches) of same institution.

Younger age, right hemicolectomy, larger tumor, higher tumor stage, higher caseload of surgeons, and patients at Linkou branch with an odds ratio (OR) as high as 23 (95% CI, 17-31) were independently associated with a higher frequency of ≥12 examined nodes.

Patients with examined node number of <12 had a greater risk of recurrence within stages II and III (stage II: adjusted OR 1.88, 95% CI 1.27-2.79; stage III: adjusted OR 1.58, 95% CI 1.15-2.17) but not within stage I (OR 0.73, 95% CI 0.23-2.24).

CONCLUSIONS: The results confirm that factors influencing nodal harvest are multifactorial and the examined LN number of 12 or more is associated with an increased long-term survival in stages II-III colon cancer.

It is possible to adequately sample and examine a sufficient number of nodes in the majority of colon cancer specimens by standardized conventional methods.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] N Engl J Med. 2005 Dec 22;353(25):2654-66 [16371631.001]

[Cites] Ann N Y Acad Sci. 2000 Jun;910:62-73; discussion 73-4 [10911906.001]

[Cites] Dis Colon Rectum. 2009 Feb;52(2):260-7 [19279421.001]

[Cites] J Clin Oncol. 1999 Sep;17(9):2896-900 [10561368.001]

[Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308 [15537574.001]

[Cites] Ann Surg. 2009 Apr;249(4):602-7 [19300229.001]

[Cites] J Gastroenterol Hepatol. 1991 Jul-Aug;6(4):325-44 [1912440.001]

[Cites] Cancer. 1998 Aug 15;83(4):666-72 [9708929.001]

[Cites] Ann Surg. 2007 Jun;245(6):858-63 [17522509.001]

[Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]

[Cites] Ann Surg. 2007 Jun;245(6):846-57 [17522508.001]

[Cites] Colorectal Dis. 2008 Feb;10(2):157-64 [17477849.001]

[Cites] N Engl J Med. 1985 Jun 20;312(25):1604-8 [4000199.001]

[Cites] Ann Surg Oncol. 2009 Mar;16(3):585-93 [19116751.001]

[Cites] J Gastrointest Surg. 2002 Nov-Dec;6(6):883-88; discussion 889-90 [12504228.001]

[Cites] J Clin Oncol. 2009 Dec 20;27(36):6166-71 [19901106.001]

[Cites] Am J Surg. 2007 Sep;194(3):349-54 [17693281.001]

[Cites] Arch Surg. 2008 Nov;143(11):1050-5; discussion 1055 [19015462.001]

[Cites] Eur J Cancer. 2005 Jan;41(2):272-9 [15661553.001]

[Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):433-41 [17374833.001]

[Cites] Ann Surg. 2004 Oct;240(4):624-8; discussion 628-30 [15383790.001]

[Cites] J Clin Oncol. 2003 Aug 1;21(15):2912-9 [12885809.001]

[Cites] JAMA. 2007 Nov 14;298(18):2149-54 [18000198.001]

[Cites] Ann Surg Oncol. 2008 Jan;15(1):46-51 [17985187.001]

[Cites] Ann Surg Oncol. 2003 Apr;10(3):213-8 [12679304.001]

[Cites] Cancer. 2001 Jul 15;92(2):452 [11466702.001]

[Cites] J Clin Oncol. 2005 Dec 1;23(34):8706-12 [16314630.001]

[Cites] Gastroenterology. 1996 Mar;110(3):682-7 [8608876.001]

[Cites] J Clin Oncol. 2006 Feb 20;24(6):878-83 [16418493.001]

[Cites] J Am Coll Surg. 2008 Feb;206(2):247-54 [18222376.001]

[Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]

[Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71 [12513963.001]

[Cites] Arch Surg. 2010 Jan;145(1):12-7 [20083749.001]

[Cites] Ann Surg. 2002 Apr;235(4):458-63 [11923600.001]

[Cites] Am J Surg Pathol. 2002 Feb;26(2):179-89 [11812939.001]

[Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]

[Cites] Eur J Cancer. 2005 Sep;41(14):2071-8 [16125926.001]

[Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):219-25 [15687365.001]

(PMID = 20676662.001).

[ISSN] 1432-1262

[Journal-full-title] International journal of colorectal disease

[ISO-abbreviation] Int J Colorectal Dis

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Adjuvant chemotherapy for colon cancer].

BACKGROUND: Radical resection is the main treatment for adenocarcinoma of the colon.

The background for adjuvant chemotherapy of colon cancer is presented.

RESULTS AND INTERPRETATION: Cure rates after curative resections of colon cancer (stage III) are improved by about 12% if patients are treated with adjuvant chemotherapy with oxaliplatin combined with 5-fluoruracil and folinat (or capecitabine) for 6 months.

Certain subgroups of stage II (Dukes' stage B) are also likely to benefit from adjuvant chemotherapy.

[MeSH-major] Adenocarcinoma / drug therapy. Colonic Neoplasms / drug therapy

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18049502.001).

[ISSN] 0807-7096

[Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række

[ISO-abbreviation] Tidsskr. Nor. Laegeforen.

[Language] nor

[Publication-type] English Abstract; Journal Article; Review

[Publication-country] Norway

[Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents

[Number-of-references] 35

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Case of adenosquamous carcinoma of the ascending colon.

Adenocarcinoma accounts for most of the malignant tumors originating from the colon, whereas adenosquamous carcinoma is rare, accounting for about 0.1% of all colon cancers.

We present herein a case of adenosquamous carcinoma of the ascending colon.

A barium enema examination and lower gastrointestinal endoscopy showed a type 3 tumor in the ascending colon, and a biopsy confirmed the diagnosis of adenosquamous carcinoma.

Right hemicolectomy was performed, and the tumor was diagnosed as a stage III advanced colon cancer.

A search of Japanese literature over the past 25 years yielded 70 patients with adenosquamous carcinoma of the colon, and the clinicopathological features are discussed herein.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18781050.001).

[ISSN] 1345-4676

[Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi

[ISO-abbreviation] J Nippon Med Sch

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Demographics, pathologic patterns and long-term survival in operable colon cancers: local experience in Pakistan.

BACKGROUND: Colon cancer is a common malignancy with its incidence reportedly rising in Asian countries, including Pakistan.

There are no comprehensive data available from Pakistan which focus on associations of various factors with long-term survival of colon cancer.

METHODOLOGY: In this retrospective study adult patients with colon cancer diagnosed through 2000-2003 were included.

Of the total, 49.5% of the patients had right sided (mortality rate 51.6%), 10.8% had transverse colon, (mortality rate 37.5%), 7.5% had descending colon (mortality rate 66.7%) and 32.2% had sigmoid colon (mortality rate 40.9%) cancers.

Stage I disease on diagnosis was found in 16%, stage II in 42.7 (mortality 40 %) and stage III in 41.3% (mortality 70 %).

Most patients had pure adenocarcinoma while a mucinous type differentiation was seen in 19.7%, 3% had signet ring morphology, 1.5% adeno-squamous carcinoma and similar number with neuroendocrine differentiation.

CONCLUSION: Colon cancer in Pakistan commonly presents at an advanced stage, there is a male preponderance, and relatively mean younger age at presentation for males is seen.

Advanced stage and lymph node involvement along with poorly differentiated pathology, signet ring or mucinous morphology, location in descending colon, positive surgical margins and removal of less than twelve lymph nodes are factors associated with poor long term survival.

There is a need to reinforce information about colon cancer and larger studies from the region are needed to confirm the factors analyzed here.

[MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Neoplasm Recurrence, Local / mortality. Survivors

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19640173.001).

[ISSN] 2476-762X

[Journal-full-title] Asian Pacific journal of cancer prevention : APJCP

[ISO-abbreviation] Asian Pac. J. Cancer Prev.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Thailand

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Colon cancer in Iceland 1955-2004. Study on epidemiology, histopathology and gender difference].

OBJECTIVE: Colon cancer is the third most common cancer in Iceland.

The aim of this study was to analyze the epidemiology and histopathology of colon cancer in Iceland, resection rate and the difference between men and women.

MATERIAL AND METHODS: Pathology and autopsy reports for all patients diagnosed with colon cancer between 1955 and 2004 where reviewed.

Most tumors were located in the sigmoid colon (35%).

Adenocarcinomas where 84% and mucinous adenocarcinoma 7%.

Altogether 7% of cases were TNM-stage I, 32% were stage II, 24% stage III, 21% in stage IV and stage was unknown in 16% of cases.

CONCLUSION: Incidence of colon cancer increased considerably, mainly for men.

Surgical rate and pathology of colon cancer is similar to that reported elsewhere except that there are somewhat fewer cases in TNM-stage I.

[MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma, Mucinous / epidemiology. Colonic Neoplasms / epidemiology

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Laeknabladid. 2009 Jun;95(6):419 [19491405.001]

(PMID = 19491407.001).

[ISSN] 0023-7213

[Journal-full-title] Læknablađiđ

[ISO-abbreviation] Laeknabladid

[Language] ice

[Publication-type] Comparative Study; English Abstract; Journal Article

[Publication-country] Iceland

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic significance of metastatic lymph node ratio in node-positive colon carcinoma.

BACKGROUND: The aim of this study was to evaluate the prognostic significance of the lymph node ratio between metastatic and examined lymph nodes (LNR) in patients with stage III colon cancer.

METHODS: A review was made of 201 patients (106 men) with stage III colon cancer of R0 resection.

CONCLUSIONS: Ratio-based LN staging, which reflects the number of LNs examined and the quality of LN dissection, is a potent modality for prognostic stratification in patients with LN-positive colon cancer.

[MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Ann Surg Oncol. 2007 Aug;14(8):2175-6 [17525836.001]

(PMID = 17253102.001).

[ISSN] 1068-9265

[Journal-full-title] Annals of surgical oncology

[ISO-abbreviation] Ann. Surg. Oncol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Multivisceral resection for colon cancer: analysis of prognostic factors.

BACKGROUND/AIMS: To assess outcome of multivisceral resection in colon cancer patients and to identify predictors of survival.

METHODS: One hundred and thirteen consecutive patients with primary locally advanced colon cancer infiltrating adjacent organs undergoing multivisceral resection between 1998 and 2007 were reviewed.

The diagnosis was conventional adenocarcinoma in 94 patients.

Hematochezia and adjuvant chemotherapy were independent factors of favorable outcome and grade G3 and tumor stage III-IV of poor survival.

CONCLUSION: Hematochezia and adjuvant chemotherapy were associated with a better survival, and poorly differentiated tumors and stage IV disease with a poor survival.

[MeSH-minor] Abdomen, Acute. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Gastrointestinal Hemorrhage / complications. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Recurrence

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20571272.001).

[ISSN] 1421-9883

[Journal-full-title] Digestive surgery

[ISO-abbreviation] Dig Surg

[Language] eng

[Publication-type] Journal Article

[Publication-country] Switzerland

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Histopathological factors as predictors for survival in colon and rectal cancers.

We included in our study 273 patients with colon and rectal cancers admitted in Surgical Clinic of Military Hospital of Craiova in which we evaluate the clinical-pathological features, location of the distant metastasis, postoperative staging, curability and survival.

We established correlations, inside of a same stage of the disease, for pathological features (characters of the tumors, differentiation grade and location) and survival rate.

Tumor differentiation is correlated with survival only for the patients with stage II and III of the disease, perineural invasion and pathologic N stage representing important predicting factors for a shorter survival.

Peritoneal washing for cytology prior to surgery is correlated with the stage of the disease and not with tumor differentiation.

[MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18758642.001).

[ISSN] 1220-0522

[Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie

[ISO-abbreviation] Rom J Morphol Embryol

[Language] eng

[Publication-type] Evaluation Studies; Journal Article

[Publication-country] Romania

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cancer biology and necrotic changes in metastatic lymph nodes and survival of colon cancer patients.

BACKGROUND: Identifying factors that can contribute to a better understanding of tumor progression in stage III colon cancer patients continues to be an important task.

METHODS: The study included 48 consecutive colon and rectosigmoid cancer patients with stage III disease who underwent radical surgery.

[MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Lymph Nodes / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15792771.001).

[ISSN] 0002-9610

[Journal-full-title] American journal of surgery

[ISO-abbreviation] Am. J. Surg.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic impact of ERβ and MMP7 expression on overall survival in colon cancer.

Estrogen receptor beta (ERβ) is the most highly expressed protein in patients with colon cancer.

We have previously shown that endocrine therapy can inhibit MMP7 expression in colon cancer cells.

In this study, we aim to identify the prognostic effects and correlation of ERβ and MMP7 in the context of colon cancer.

ERβ and MMP7 levels were assessed by immunohistochemistry in normal mucosa and tumoral tissues from 423 patients with stage I-III colon cancer.

In the subset of patients with high expression levels of tumoral nuclear ERβ, high expression of MMP7 was related to OS and CSS among colon cancer patients with high expression of ERβ.

In conclusion, our results suggest that low expression of ERβ was a risk factor in colon cancer, and high expression of MMP7 was an independent prognostic factor of ERβ-positive patients with colon cancer.

[MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Colonic Neoplasms / metabolism. Colonic Neoplasms / mortality. Estrogen Receptor beta / metabolism. Matrix Metalloproteinase 7 / metabolism

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Ann Surg. 2001 Jun;233(6):786-92 [11371737.001]

[Cites] J Invest Dermatol. 1995 Aug;105(2):190-6 [7636300.001]

[Cites] Eur J Cancer. 2003 Jun;39(9):1251-8 [12763213.001]

[Cites] J Clin Endocrinol Metab. 1997 Dec;82(12):4258-65 [9398750.001]

[Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5925-30 [8650195.001]

[Cites] Hum Pathol. 2001 Sep;32(9):940-4 [11567223.001]

[Cites] N Engl J Med. 2004 Mar 4;350(10):991-1004 [14999111.001]

[Cites] Oncol Rep. 2005 Jul;14(1):17-21 [15944762.001]

[Cites] Endocr Relat Cancer. 2004 Sep;11(3):537-51 [15369453.001]

[Cites] J Exp Clin Cancer Res. 2009 Sep 29;28:132 [19785773.001]

[Cites] JAMA. 2002 Jul 17;288(3):321-33 [12117397.001]

[Cites] Endocr Relat Cancer. 2005 Jun;12(2):455-69 [15947116.001]

[Cites] Cancer. 2000 May 15;88(10):2398-424 [10820364.001]

[Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]

[Cites] Dig Dis Sci. 2002 Dec;47(12):2720-8 [12498292.001]

[Cites] Cell Oncol. 2009;31(3):235-47 [19478391.001]

[Cites] Cancer Res. 2000 Jan 15;60(2):245-8 [10667568.001]

[Cites] Int J Colorectal Dis. 2009 Aug;24(8):875-84 [19421758.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2959-64 [16477031.001]

[Cites] J Pathol. 2005 Sep;207(1):53-60 [15954165.001]

(PMID = 20680712.001).

[ISSN] 1423-0380

[Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

[ISO-abbreviation] Tumour Biol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogen Receptor beta; EC 3.4.24.23 / Matrix Metalloproteinase 7

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cancer staging and survival in colon cancer is dependent on the quality of the pathologists' specimen examination.

Correct staging of colon cancer is decisive regarding further oncological treatment, surveillance and prediction of long-term survival.

Data from the colon cancer register (1997-2002) of the Uppsala/Orebro, Sweden, health care region were analysed and the seven pathology departments in this region were compared.

Included were 3735 patients who had undergone resection of a colon cancer.

Survival in stage II was lower when fewer than 12 nodes were examined or when the number of nodes sampled was not given (P = 0.001, log-rank test).

In stage III, those with at the most 3 nodes positive (N1) had a better survival than those with 4 or more nodes positive (N2) (P < 0.001, log-rank test).

An index of metastases (IM), derived from the number of nodes with metastases divided by the number of nodes examined, was calculated for stage III tumours.

Examination of 12 nodes is necessary to assure stage III cases with the median IM (0.32), whereas 20 nodes are necessary to assure 90% of cases with the lower quartile of IM (0.16).

The prognostic information of the IM was higher than that of the N-stage.

An index of metastases (IM) is a possible basis for guidance in the choice of adjuvant treatments that appears superior to that of N-stage.

[MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16125926.001).

[ISSN] 0959-8049

[Journal-full-title] European journal of cancer (Oxford, England : 1990)

[ISO-abbreviation] Eur. J. Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The relationship of lymph node dissection and colon cancer survival in the Veterans Affairs Central Cancer Registry.

BACKGROUND: The extent of lymphadenectomy in colon cancer may impact potential to cure and accuracy of staging.

METHODS: The Veterans Affairs Central Cancer Registry database was queried for TNM stage I-III colon adenocarcinoma patients and yielded 5,823 individuals.

RESULTS: The overall survival (OS) in stage II patients was greater with the higher number of lymph node (LN) examined.

For stage II patients, the 5-year OS was 34%, 43%, 47%, and 55% for the lowest to highest quartiles (P = .007).

For stage III patients, the 5-year OS was 31%, 27%, 38%, and 53% for the lowest to highest quartiles (not significant overall).

CONCLUSIONS: More extensive lymphadenectomy is associated with improved OS in stage II colon cancer patients.

[MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Colonic Neoplasms / mortality. Colonic Neoplasms / surgery. Lymph Node Excision

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17693281.001).

[ISSN] 1879-1883

[Journal-full-title] American journal of surgery

[ISO-abbreviation] Am. J. Surg.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Inadequate quality of surveillance after curative surgery for colon cancer.

BACKGROUND: Colon cancer patients are at risk for recurrence.

The objective of this study is to analyze the quality of surveillance after curative surgery for colon cancer among a cohort of Swiss patients.

PATIENTS AND METHODS: After curative surgery, 129 stage I-III colon cancer patients were followed by chart review, questionnaires, and phone interviews.

CONCLUSIONS: The quality of surveillance after curative surgery for colon cancer among a cohort of Swiss patients is inadequate.

[MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Continuity of Patient Care

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20429036.001).

[ISSN] 1534-4681

[Journal-full-title] Annals of surgical oncology

[ISO-abbreviation] Ann. Surg. Oncol.

[Language] eng

[Publication-type] Journal Article; Multicenter Study

[Publication-country] United States

[Chemical-registry-number] 0 / Carcinoembryonic Antigen

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer.

OBJECTIVE: Epithelial ovarian cancer kills more women than all other gynecologic malignancies combined because of our inability to detect early-stage disease.

Ultrasonography has demonstrated usefulness in the detection of ovarian cancer in asymptomatic women, but its value for the detection of early-stage epithelial ovarian cancer in women of increased risk is uncertain.

We examined the usefulness of sonography in the detection of early-stage epithelial ovarian cancer in asymptomatic high-risk women who participated in the National Ovarian Cancer Early Detection Program.

Increased risk includes women with at least 1 affected first-degree relative with ovarian cancer; a personal history of breast, ovarian, or colon cancer; > or =1 affected first- and second-degree relatives with breast and or ovarian cancer; inheritance of a breast cancer mutation from an affected family member, or membership within a recognized cancer syndrome.

The detected malignancies were fallopian tube carcinoma (stage IIIC; n = 4 women), primary peritoneal carcinoma (n = 4 women; stage IIIA, 1 woman; stage IIIB, 2 women; stage IIIC, 1 woman), epithelial ovarian cancer (stages IIIA and IIIB; n = 2 women), and endometrial adenocarcinoma (stage IA; n = 2 women).

A total of 184 women with genetic predisposition (breast cancer positive) have undergone a prophylactic bilateral salpingo-oophorectomy; 23% of these procedures found atypical hyperplasia, and unexpectedly, 2 women (1%) were found to have stage III (A and B) primary peritoneal carcinoma.

CONCLUSION: This study demonstrates the limited value of diagnostic ultrasound examination as an independent modality for the detection of early-stage epithelial ovarian cancer in asymptomatic women who are at increased risk for disease.

Genetic Alliance. consumer health - Ovarian cancer.

Genetic Alliance. consumer health - Ovarian epithelial cancer.

MedlinePlus Health Information. consumer health - Ovarian Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15846205.001).

[ISSN] 0002-9378

[Journal-full-title] American journal of obstetrics and gynecology

[ISO-abbreviation] Am. J. Obstet. Gynecol.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / P50 CA83639; United States / NCI NIH HHS / CA / R01 CA01015; United States / NCI NIH HHS / CA / R01 CA82562; United States / NCI NIH HHS / CA / R01 CA89503; United States / NCI NIH HHS / CA / UO1CA85133

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers.

OBJECTIVE: Colon cancers with high frequency microsatellite instability (MSI-H) are preferentially located in the proximal colon.

Given that 15-20% of sporadic colon cancers are MSI-H, we determined whether tumor site-specific differences in clinicopathological variables, biomarkers, and prognosis are due to inclusion of MSI-H cases.

METHODS: TNM stage II and III primary colon carcinomas (N = 528) from patients enrolled in 5-fluorouracil-based adjuvant trials were analyzed for MSI using 11 microsatellite markers.

RESULTS: MSI-H was found in 95 (18%) colon cancers.

CONCLUSIONS: Tumor site-related differences in clinicopathological variables, biomarkers, and prognosis of sporadic colon cancers can be explained by the inclusion of MSI-H cases.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17026563.001).

[ISSN] 0002-9270

[Journal-full-title] The American journal of gastroenterology

[ISO-abbreviation] Am. J. Gastroenterol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / U01 CA074800; United States / NCI NIH HHS / CA / CA 104683

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.

PATIENTS AND METHODS: We analyzed data from Intergroup trial 0089 of adjuvant chemotherapy for stage II and III patients with colon cancer, in which all patients received fluorouracil-based therapy.

Covariates included in the models were age, sex, tumor stage, grade, histology, number of positive LNs, number of LNs removed, and LNR.

[MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / therapy. Lymphatic Metastasis / pathology

Genetic Alliance. consumer health - Metastatic cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16314630.001).

[ISSN] 0732-183X

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Colorectal carcinoma: a retrospective, descriptive study of age, gender, subsite, stage, and differentiation in Iran from 1995 to 2001 as observed in Tehran University.

These factors also are evaluated in conjunction with disease stage and tumor differentiation at the time of diagnosis.

METHODS: Data from 419 patients from a population that receives no screening between April 1995 and March 2001 operated on in the Cancer Institute and Imam Khomieni Hospital with a diagnosis of colorectal cancer were used to describe distribution of the colorectal carcinoma by age, gender, tumor subsite and pathology, and stage at diagnosis.

RESULTS: There were 403 (96.2 percent) cases of adenocarcinoma.

Patients were divided into two age groups (40 years and younger, and older than 40 years); 16.4 percent of patients had tumors in the proximal colon and 83.6 percent in distal parts.

Most patients were Stage II and III (48.1 and 33.4 percent, respectively).

Most patients in the younger age group were Stage III (45 percent) and in the older age group were Stage II (53.2 percent; P<0.001).

There were no differences in stage and tumor differentiation between two genders, but most of the patients with tumors in proximal colon were males (62.5 percent; P=0.1).

[MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Colorectal Neoplasms / epidemiology. Colorectal Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17525859.001).

[ISSN] 0012-3706

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Survival of patients diagnosed with either colorectal mucinous or non-mucinous adenocarcinoma: a population-based study in Canada.

Previous studies have shown conflicting results on the prognosis of colorectal mucinous adenocarcinoma.

Analyses were based on 165 colorectal mucinous and 1215 non-mucinous adenocarcinoma patients who were registered at the Ottawa Regional Cancer Centre from 1994 to 1997, with follow-up extending to December 31, 2001.

For colon, rectum and both combined, the distribution for age at diagnosis, stage and treatment of patients with mucinous adenocarcinoma was similar to that of non-mucinous patients (all p > or = 0.12).

Overall, no statistically significant differences were noted in 5-year relative survival between mucinous and non-mucinous carcinoma for colon, rectum and their combination (p > or = 0.35 for each).

However, when the stages were considered separately, patients with stage III mucinous carcinoma had worse survival than patients with non-mucinous carcinoma for both sites.

Multivariate analysis of combined data for colon and rectal cancers indicated that independent significant prognostic factors were stage for mucinous, with age and grade as well as stage for non-mucinous carcinoma.

In conclusion, no significant differences in stage distribution and overall survival were found between mucinous and non-mucinous patients for colorectal cancer.

[MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma, Mucinous / mortality. Colorectal Neoplasms / mortality

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19287969.001).

[ISSN] 1019-6439

[Journal-full-title] International journal of oncology

[ISO-abbreviation] Int. J. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Greece

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Colon cancer prognosis prediction by gene expression profiling.

This study assessed the possibility to build a prognosis predictor, based on microarray gene expression measures, in stage II and III colon cancer patients.

This study suggests that one can build an accurate prognosis predictor for stage II and III colon cancer patients, based on gene expression measures, and one can use either tumour or non-neoplastic mucosa for this purpose.

[MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Gene Expression Profiling. Genetic Markers. Oligonucleotide Array Sequence Analysis

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16091735.001).

[ISSN] 0950-9232

[Journal-full-title] Oncogene

[ISO-abbreviation] Oncogene

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Genetic Markers

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment.

AIM: Adjuvant chemotherapy is recommended for stage III colon cancer.

The aim of this study was to identify important prognostic factors among patients with colon cancer receiving adjuvant 5-FU-based treatment.

METHODS: Data sets of 855 colon cancer patients treated between 1992 and 1999 within a multicenter adjuvant trial comparing 5-FU modulation with folinic acid or interfereron-alpha were examined.

In the future, this may result in adjuvant treatment of stage III colon cancer adjusted for the risk of substages.

[MeSH-major] Adenocarcinoma / mortality. Antimetabolites, Antineoplastic / therapeutic use. Colonic Neoplasms / mortality. Fluorouracil / therapeutic use

Hazardous Substances Data Bank. FLUOROURACIL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18313881.001).

[ISSN] 1532-2157

[Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

[ISO-abbreviation] Eur J Surg Oncol

[Language] eng

[Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Immunologic Factors; 0 / Interferon-alpha; 12001-76-2 / Vitamin B Complex; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] SirT1 is an inhibitor of proliferation and tumor formation in colon cancer.

Immunohistochemical staining revealed high level SirT1 in normal colon mucosa and benign adenomas.

SirT1 overexpression was observed in approximately 25% of stage I/II/III colorectal adenocarcinomas but rarely found in advanced stage IV tumors.

These results suggest a rationale for the use of SirT1 activators and inhibitors in the prevention and treatment of colon cancer.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. FLUOROURACIL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nature. 2000 Feb 17;403(6771):795-800 [10693811.001]

[Cites] Science. 2000 Sep 22;289(5487):2126-8 [11000115.001]

[Cites] Nature. 2001 Mar 8;410(6825):227-30 [11242085.001]

[Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]

[Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]

[Cites] Nature. 2003 Sep 11;425(6954):191-6 [12939617.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10794-9 [12960381.001]

[Cites] Cell. 2004 Feb 20;116(4):551-63 [14980222.001]

[Cites] EMBO J. 2004 Jun 16;23(12):2369-80 [15152190.001]

[Cites] Science. 2004 Jul 16;305(5682):390-2 [15205477.001]

[Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]

[Cites] Cancer Res. 1994 Nov 15;54(22):5947-52 [7954427.001]

[Cites] Nature. 2005 Mar 3;434(7029):113-8 [15744310.001]

[Cites] Cell Metab. 2005 Jul;2(1):67-76 [16054100.001]

[Cites] Cell Metab. 2005 Aug;2(2):105-17 [16098828.001]

[Cites] Cell. 2005 Nov 4;123(3):437-48 [16269335.001]

[Cites] Cancer Res. 2005 Nov 15;65(22):10457-63 [16288037.001]

[Cites] Mol Cell Biol. 2006 Jan;26(1):28-38 [16354677.001]

[Cites] Oncogene. 2006 Jan 12;25(2):176-85 [16170353.001]

[Cites] PLoS Biol. 2006 Feb;4(2):e31 [16366736.001]

[Cites] Cancer Res. 2006 Apr 15;66(8):4368-77 [16618762.001]

[Cites] Nat Cell Biol. 2006 Sep;8(9):1025-31 [16892051.001]

[Cites] Mol Cell Biol. 2006 Nov;26(21):8122-35 [16923962.001]

[Cites] Nature. 2006 Nov 16;444(7117):337-42 [17086191.001]

[Cites] Cell. 2006 Dec 15;127(6):1109-22 [17112576.001]

[Cites] Mol Cell. 2007 Feb 23;25(4):543-57 [17317627.001]

[Cites] Arch Dermatol Res. 2007 May;299(2):103-6 [17180656.001]

[Cites] Mol Cell. 2007 Jul 6;27(1):149-62 [17612497.001]

[Cites] Cancer Res. 2007 Jul 15;67(14):6612-8 [17638871.001]

[Cites] Oncogene. 2007 Aug 13;26(37):5489-504 [17694089.001]

[Cites] Biochem J. 2007 Nov 1;407(3):451-60 [17620057.001]

[Cites] Biotechnol J. 2007 Nov;2(11):1360-8 [17806102.001]

[Cites] Nature. 2007 Nov 29;450(7170):712-6 [18046409.001]

[Cites] Mol Biol Cell. 2008 Mar;19(3):1210-9 [18184747.001]

[Cites] PLoS One. 2008;3(4):e2020 [18414679.001]

[Cites] Cancer Cell. 2008 Oct 7;14(4):312-23 [18835033.001]

(PMID = 19433578.001).

[ISSN] 1083-351X

[Journal-full-title] The Journal of biological chemistry

[ISO-abbreviation] J. Biol. Chem.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA112215; United States / NCI NIH HHS / CA / R01 CA112215-03; United States / NCI NIH HHS / CA / CA121291; United States / NCI NIH HHS / CA / R01 CA121291; United States / NCI NIH HHS / CA / CA112215-03

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Small Interfering; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins; U3P01618RT / Fluorouracil

[Other-IDs] NLM/ PMC2709385

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status.

BACKGROUND: Evidence suggests that epidermal growth factor receptor (EGFR)-activation status may better predict the clinical behaviour of colon cancers than does EGFR expression.

However, the prognostic effect of phospho-EGFR in primary colon cancer remains undefined.

METHODS: Phospho-EGFR (Tyr-1173) and EGFR expression were analysed by immunohistochemistry (IHC) in tissue microarrays of TNM stage II and III colon cancers from completed adjuvant therapy trials (n=388).

Although phospho-EGFR was unrelated to clinicopathological variables, strong EGFR intensity was associated with higher tumour stage (P=0.03).

Stage and lymph node number were prognostic for DFS and OS, and histological grade for OS.

EGFR was an independent predictor of DFS (P=0.042) after adjustment for stage, histological grade, age, and MMR status.

COS Scholar Universe. author profiles.

PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .

Hazardous Substances Data Bank. FLUOROURACIL .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2004 May 1;22(9):1572-82 [15117979.001]

[Cites] Mol Cell Biol. 2003 Nov;23(21):7875-86 [14560030.001]

[Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]

[Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]

[Cites] Clin Cancer Res. 2004 Oct 1;10(19):6487-501 [15475436.001]

[Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]

[Cites] Cancer Res. 1993 Dec 15;53(24):5849-52 [8261392.001]

[Cites] J Biol Chem. 1994 Jul 15;269(28):18674-8 [8034616.001]

[Cites] Eur J Surg Oncol. 1995 Jun;21(3):269-75 [7781795.001]

[Cites] Biochemistry. 1995 Dec 19;34(50):16456-66 [8845374.001]

[Cites] Gastroenterology. 1996 Mar;110(3):669-74 [8608874.001]

[Cites] Cancer Res. 1998 Apr 15;58(8):1713-8 [9563488.001]

[Cites] Clin Cancer Res. 1995 Jan;1(1):19-31 [9815883.001]

[Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]

[Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1295-303 [10433618.001]

[Cites] J Biol Chem. 1999 Sep 10;274(37):26091-7 [10473558.001]

[Cites] Ann Oncol. 2005 Jan;16(1):102-8 [15598946.001]

[Cites] J Clin Oncol. 2005 Mar 20;23(9):1803-10 [15677699.001]

[Cites] Int J Oncol. 2005 Aug;27(2):317-25 [16010411.001]

[Cites] Mod Pathol. 2005 Oct;18(10):1350-6 [15832190.001]

[Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S59-62 [16399434.001]

[Cites] J Clin Oncol. 2006 Mar 1;24(7):1169-77 [16505437.001]

[Cites] Cancer Res. 2006 Mar 1;66(5):2834-43 [16510606.001]

[Cites] Clin Cancer Res. 2006 May 1;12(9):2738-44 [16675565.001]

[Cites] Clin Colorectal Cancer. 2006 Jul;6(2):133-9 [16945169.001]

[Cites] Gastroenterology. 2006 Sep;131(3):729-37 [16952542.001]

[Cites] Br J Cancer. 2006 Dec 4;95(11):1525-8 [17088913.001]

[Cites] Int J Cancer. 2007 Mar 15;120(6):1232-8 [17187355.001]

[Cites] Lung Cancer. 2007 Mar;55(3):349-55 [17161498.001]

[Cites] J Clin Oncol. 2007 May 1;25(13):1658-64 [17470858.001]

[Cites] J Clin Oncol. 2007 Jun 1;25(16):2184-90 [17538163.001]

[Cites] Clin Cancer Res. 2007 Jun 15;13(12):3597-604 [17575224.001]

[Cites] J Clin Oncol. 2007 Oct 1;25(28):4405-13 [17906204.001]

[Cites] Ann Oncol. 2008 Dec;19(12):2033-8 [18632722.001]

[Cites] Pathology. 2009;41(4):356-60 [19404848.001]

[Cites] Curr Opin Oncol. 2009 Jul;21(4):369-73 [19444104.001]

[Cites] Clin Cancer Res. 2009 Jul 15;15(14):4531-7 [19584170.001]

[Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]

[Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]

[Cites] Cancer Res. 2000 Apr 15;60(8):2225-31 [10786688.001]

[Cites] Int J Cancer. 2000 Oct 1;88(1):77-81 [10964085.001]

[Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1521-6 [11818567.001]

[Cites] J Clin Oncol. 2002 Apr 1;20(7):1735-43 [11919229.001]

[Cites] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098.001]

[Cites] Eur J Cancer. 2002 May;38(8):1065-71 [12008194.001]

[Cites] Eur J Cancer. 2002 Nov;38(17):2258-64 [12441262.001]

[Cites] Eur J Cancer. 2003 Jul;39(10):1348-54 [12826036.001]

[Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]

[Cites] Virchows Arch. 2003 Aug;443(2):115-21 [12802583.001]

[Cites] Clin Cancer Res. 2004 May 1;10(9):3069-75 [15131045.001]

(PMID = 19997103.001).

[ISSN] 1532-1827

[Journal-full-title] British journal of cancer

[ISO-abbreviation] Br. J. Cancer

[Language] ENG

[Grant] United States / NIDDK NIH HHS / DK / P30 DK084567; United States / NCI NIH HHS / CA / R01 CA104683; United States / NCI NIH HHS / CA / CA 104683

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural

[Publication-country] England

[Chemical-registry-number] 0 / Neoplasm Proteins; 21820-51-9 / Phosphotyrosine; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; U3P01618RT / Fluorouracil

[Other-IDs] NLM/ PMC2813748